PD-1/PD-L1 inhibitor plus chemotherapy improves overall survival in advanced gastric and esophageal junction cancer
PD-1 Inhibitors Plus Chemotherapy Improve Survival in Gastric Cancer
This meta-analysis of 6,517 patients found that PD-1/PD-L1 inhibitor plus chemotherapy significantly improved overall survival (HR, 0.79) an…
Combining PD-1 or PD-L1 inhibitors with chemotherapy shows improved survival and response rates for patients with advanced gastric or esopha…
SCRT plus ICI associated with higher CR and pCR rates than LCRT in rectal cancer
Specific radiation types may improve outcomes for rectal cancer patients
This meta-analysis of 972 patients with pMMR or MSS locally advanced rectal cancer found that SCRT plus ICI yielded higher CR and pCR rates …
Adding certain immunotherapy drugs to specific types of radiation may improve response rates for patients with advanced rectal cancer.
PD-1/PD-L1 inhibitors provide superior overall survival compared to chemotherapy or cetuximab in platinum-refractory HNSCC
Newer drugs show better survival for advanced head and neck cancer
This meta-analysis of 5 RCTs involving 1,700 patients found that PD-1/PD-L1 inhibitors resulted in superior overall survival (HR: 0.80) comp…
A review of clinical trials shows that certain immunotherapy drugs offer better survival rates and fewer severe side effects than traditiona…
PD-1 and PD-L1 inhibitors increase the risk of skin rash in cancer patients
Immunotherapy drugs increase rash risks for cancer patients
This meta-analysis evaluated the risk of developing rashes in cancer patients treated with PD-1 or PD-L1 inhibitors, both alone and in combi…
New data shows that certain immunotherapy drugs used to treat cancer significantly increase the risk of developing skin rashes.
Viral mimicry induction via epigenetic therapies and DNA damage may convert cold tumors to hot
New Strategies May Help Overcome Cancer Treatment Resistance
This narrative review explores strategies to overcome immune checkpoint blockade resistance in solid tumors. The authors suggest that induci…
Scientists are exploring ways to turn "cold" tumors into "hot" ones to help patients whose cancer is no longer responding to immunotherapy.
PD-(L)1 plus VEGF monoclonal antibody shows most favorable overall survival in advanced hepatocellular carcinoma
New data identifies best immunotherapy combinations for advanced liver cancer
This meta-analysis of 15 phase III trials evaluated first-line immunotherapy combinations for advanced hepatocellular carcinoma. The analysi…
A large review of over 9,000 patients reveals which drug combinations offer the best survival rates and safety for advanced liver cancer.
Combination of PD-1/PD-L1 inhibitors and chemotherapy shows no overall survival benefit in mCRPC
Combination therapy shows mixed results for advanced prostate cancer
This meta-analysis evaluated the addition of PD-1 or PD-L1 inhibitors to chemotherapy for patients with metastatic castration-resistant pros…
Adding immunotherapy to chemotherapy for advanced prostate cancer may not improve survival for all patients and can lead to more severe side…
Forty-seven clinically relevant late-phase programs identify development trajectories for PD-1 and PD-L1 therapies through 2030
47 late-phase programs aim to improve PD-1/PD-L1 cancer therapies
This narrative review analyzes registry-derived clinical trial data to identify future directions for PD-1 and PD-L1 inhibitor therapies. Th…
A new review maps 47 late-phase programs working to overcome limits of PD-1/PD-L1 cancer treatments through 2030.
Primary and acquired resistance to immune checkpoint inhibitors in NSCLC involves antigen presentation and TME remodeling
Understanding why some lung cancer treatments do not work for every patient
This systematic review synthesizes mechanisms of primary and acquired resistance to PD-1/PD-L1 inhibitors in patients with non-small cell lu…
Doctors are studying why certain immune-boosting drugs fail to stop lung cancer growth. New insights help find better ways to treat patients…
Comparative Efficacy of PD-1 and PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
Analysis shows PD-1 inhibitors may outperform PD-L1 for lung cancer
A meta-analysis suggests that PD-1 inhibitors combined with chemotherapy offer superior survival outcomes compared to PD-L1 inhibitors plus …
A large analysis of over 14,000 patients suggests that certain types of immunotherapy combined with chemotherapy may offer better survival r…
Multidimensional models incorporating genomic and microenvironment features likely outperform single-analyte tests to predict immunotherapy response
Multi-Omic Biomarkers May Improve Lung Cancer Treatment Predictions
This narrative review explores the integration of chemokine signatures and multi-omic biomarkers to predict immune checkpoint inhibitor resp…
New research suggests that combining multiple biological markers can better predict how lung cancer patients will respond to immunotherapy.
PD-1/PD-L1 inhibitors plus chemotherapy improve survival in advanced endometrial cancer
Immunotherapy combo extends life in advanced endometrial cancer
A meta-analysis of 4,052 patients from RCTs found that adding PD-1/PD-L1 inhibitors to chemotherapy improved overall survival (median 43.7 v…
Adding immunotherapy to chemo boosted survival by over 14 months in advanced endometrial cancer, a new analysis finds.
All PD-L1 inhibitors Articles
- SCRT plus ICI associated with higher CR and pCR rates than LCRT in rectal cancer
- PD-1/PD-L1 inhibitor plus chemotherapy improves overall survival in advanced gastric and esophageal junction cancer
- PD-1/PD-L1 inhibitors provide superior overall survival compared to chemotherapy or cetuximab in platinum-refractory HNSCC
- PD-1 and PD-L1 inhibitors increase the risk of skin rash in cancer patients
- Viral mimicry induction via epigenetic therapies and DNA damage may convert cold tumors to hot
- PD-(L)1 plus VEGF monoclonal antibody shows most favorable overall survival in advanced hepatocellular carcinoma
- Combination of PD-1/PD-L1 inhibitors and chemotherapy shows no overall survival benefit in mCRPC
- Forty-seven clinically relevant late-phase programs identify development trajectories for PD-1 and PD-L1 therapies through 2030
- Primary and acquired resistance to immune checkpoint inhibitors in NSCLC involves antigen presentation and TME remodeling
- Comparative Efficacy of PD-1 and PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
- Multidimensional models incorporating genomic and microenvironment features likely outperform single-analyte tests to predict immunotherapy response
- PD-1/PD-L1 inhibitors plus chemotherapy improve survival in advanced endometrial cancer
- Systematic review of immune checkpoint inhibitors in cancer efficacy and safety
- Meta-analysis shows platinum-etoposide plus PD-1/PD-L1 inhibitor improves survival in extensive-stage small-cell lung cancer
- Review of immunotherapy innovations for triple-negative breast cancer survival
- Narrative review discusses immune checkpoint inhibitors in lung cancer patients
- Systematic review examines immunotherapy resistance mechanisms and strategies in hepatocellular carcinoma patients
- Systematic review examines immune checkpoint inhibitors, innate immunity, and immune-related adverse events in cancer patients
- PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
- Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors